Another trial (NCT05119335) examines NKT2152, a HIF2α inhibitor, in advanced (ccRCC), exploring its potential to disrupt cancer growth by inhibiting both HIF2α and CDK4/6 (98). Here, EPAS1 is linked to nonpapillary renal cell carcinoma.